米氮平治疗脑梗死后抑郁临床疗效观察

目的探讨米氮平治疗脑梗死后抑郁的疗效及安全性。方法将81例脑梗死后抑郁患者随机分为两组,分别给予米氮平和阿米替林治疗,疗程6周。于0、1、2、4、6周进行HAMD、CGI—SI、TESS评定。结果治疗后米氮平组有效率87%,阿米替林组84%,两组相比差异无显著性(P>0.05)。米氮平组不良反应发生率较阿米替林组小。结论米氮平治疗脑梗死后抑郁疗效确切,安全性较高。

AIM To investigate the efficacy and adverse reactions of mirtazapine in the treatment of depression after cerebral infarction . METHODS Eighty-one patients with depression after cerebral infarction were diveded into two groups, separately treated with mirtazapine or amitriptine for 6 weeks. To evaluate with HAMD, CGI SI, TESS at 0, 1, 2, 4, 6weeks RESULTS The curative effect was 87% in mirtazapine group and 84 % ine the amitriptine group. There was no significant difference beween two groups （P〉0.05）.In addition, the adverse reactions in mirtazapine group was less than that in amitriptine group. CONCLUSION Mirtazapine has batter efficacy and less adverse reactions in the treatment of depresion after cerebral infarction.